Serum Microrna as a Marker of Multiple Myeloma

Authors

KUBICZKOVÁ Lenka ŠEVČÍKOVÁ Sabina DEMENTYEVA Elena Vladimirovna KRYUKOV Fedor SLABÝ Ondřej NEKVINDOVÁ Jana RADOVÁ L. ZAHRADOVÁ Lenka POUR Luděk HÁJEK Roman

Year of publication 2013
Type Conference abstract
Citation
Description MicroRNA (miRNA) are small non-coding RNA playing a significant role in pathogenesis of multiple myeloma (MM). We have identified a specific serum miRNA profile in MM patients (pts) and correlated it with clinical parameters. Methods. 133 serum samples: 103 (51M/52F) from newly diagnosed MM pts and 30 (14M/16F) from healthy donors (HD) were tested. A screening of 667 serum miRNA was performed on 4 MM and 4 HD with TaqMan Low Density Arrays (TLDA). Expression of differentially expressed miRNA was validated by RT-PCR. Area under curve (AUC), specificity, sensitivity and correlation with clinical parameters was analyzed.Results. Based on TLDA, 14 miRNA were differentially expressed between MM and HD (p<0.05). Out of them, five miRNA were validated by RT-PCR: miR-744 (p<0.0004), miR-130a (p<0.0002), let 7d (p<0.0001) and let-7e (p<0.0001) were significantly downregulated and miR-34a (p<0.0001) was significantly upregulated. ROC analysis showed highest sensitivity (80.6%), specificity (86.7%) and AUC (0.898) for a combination of miR-34a and let-7d. Positive correlation was observed between low levels of miR-744, let-7d and let-7e and levels of hemoglobin, thrombocytes and albumin (all p=0.0001), negative correlation between low miRNA levels and levels of creatinine and beta2 microglobulin was found (all p<0.0001). Expression of miR-744, let-7d and let-7e showed an inverse correlation with ISS stage (all p<0.0001).Conclusion. Our study shows that miRNA may be a promising biomarker for MM pts.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.